Empagliflozin is drug which is being investigated in clinical trials for the oral treatment of type 2 diabetes by Boehringer Ingelheim and Eli Lilly and Company.
ZOOM – Children's exhibition, Österreichischer Rundfunk, Servus TV, McDonald's, Nissan, Sony, ÖAMTC, Dulcolax, Alpla, 3, T-Mobile, IKEA, Kurier (Tageszeitung), Schwarzkopf (Haarkosmetik), Schartner Bombe, NÖ-Card, Vereinigte Bühnen Wien.
Volasertib (also known as BI 6727) is a small molecule inhibitor of the PLK1 (polo-like kinase 1) protein being developed by Boehringer Ingelheim for use as an anti-cancer agent.
Boehringer Ingelheim was founded in Ingelheim am Rhein, Germany in 1885, where the corporate headquarters are located.There are about 4,500 employees in Biberach.
The foundation of the institute was promoted by the private company Boehringer Ingelheim, intending to branch into biotechnology, and the American partner Genentech, a biotechnology firm.
It is now marketed by various companies under licence, including Boehringer-Ingelheim and CSL.